Avoid the stress of overpaying for a stock or missing an opportunity by using the right tools and insights to evaluate Greenwich LifeSciences, Inc. before investing.

In this article, we go over a few key elements for understanding Greenwich LifeSciences, Inc.’s stock price such as:

• Greenwich LifeSciences, Inc.’s current stock price and volume
• Why Greenwich LifeSciences, Inc.’s stock price changed recently
• Upgrades and downgrades for GLSI from analysts
• GLSI’s stock price momentum as measured by its relative strength

About Greenwich LifeSciences, Inc. (GLSI)

Before we jump into Greenwich LifeSciences, Inc.’s stock price, history, target price and what caused it to recently dip, let’s take a look at some background.

Greenwich LifeSciences, Inc., a clinical-stage biopharmaceutical company, develops novel cancer immunotherapies for breast cancer and other HER2/neu-expressing cancers in the United States and Romania. Its lead product candidate is GP2, an immunotherapy, which is in Phase III clinical trial to prevent breast cancer recurrences in patients who have previously undergone surgery. The company also develops FLAMINGO-01, which is in Phase III clinical trial designed to evaluate the safety and efficacy of GLSI-100 (GP2 + GM-CSF) in HER2 positive breast cancer patients. Greenwich LifeSciences, Inc. was formerly known as Norwell, Inc. and changed its name to Greenwich LifeSciences, Inc. in March 2018. The company was incorporated in 2006 and is headquartered in Stafford, Texas.

Want to learn more about Greenwich LifeSciences, Inc.’s stock? Click the button below to subscribe to A+ Investor and get access to everything you need to know about Greenwich LifeSciences, Inc..

Greenwich LifeSciences, Inc.’s Stock Price as of Market Close

As of February 04, 2026, 4:00 PM, CST, Greenwich LifeSciences, Inc.’s stock price was $27.010.

Greenwich LifeSciences, Inc. is down 3.62% from its previous closing price of $28.025.

During the last market session, Greenwich LifeSciences, Inc.’s stock traded between $26.130 and $28.290. Currently, there are approximately 13.64 million shares outstanding for Greenwich LifeSciences, Inc..

Greenwich LifeSciences, Inc.’s trailing earnings per share are negative, so the stock does not have a meaningful P/E ratio. We suggest investors evaluate other financial metrics to understand its overall valuation.

Greenwich LifeSciences, Inc. Stock Price History

Greenwich LifeSciences, Inc.’s (GLSI) price is currently down 10.18% so far this month.

During the month of February, Greenwich LifeSciences, Inc.’s stock price has reached a high of $32.660 and a low of $26.130.

Over the last year, Greenwich LifeSciences, Inc. has hit prices as high as $34.100 and as low as $7.780. Year to date, Greenwich LifeSciences, Inc.’s stock is up 28.56%.

Sign Up to Receive a Free Special Report Showing How A+ Grades Can Help You Make Smarter Investment Decisions

What Caused Greenwich LifeSciences, Inc. Stock’s Price to Dip?

Stock prices are primarily based on seller supply and buyer demand. But have you ever wondered about what other factors affect a stock's price?

When an analyst changes their opinion of a stock by upgrading or downgrading their rating, it often leads to a sudden stock price adjustment. As of February 04, 2026, there were analysts who downgraded Greenwich LifeSciences, Inc.’s stock and analysts who upgraded over the last month.

Additionally, you'll want to evaluate Greenwich LifeSciences, Inc.’s financial health and valuation. Investors can use AAII's Value Grade, which combines six key valuation metrics like P/E and P/S ratios for a comprehensive analysis to conduct analysis on Greenwich LifeSciences, Inc.’s valuation and financial health. This approach mitigates the limitations of single-metric evaluations.

Learn how to evaluate stocks with AAII Grades and Scores with A+ Investor today.

Lastly, news and media coverage as well as recent press reports about the company or its industry may cause stock prices to fluctuate. You can check out the most recent news articles about Greenwich LifeSciences, Inc. (GLSI) by visiting AAII Stock Evaluator.

Relative Price Strength of Greenwich LifeSciences, Inc.

Relative price strength measures a stock's performance against the market, helping investors identify stocks that are outperforming benchmarks.

For AAII’s Momentum Grade, a weighted relative price strength is calculated. Follow this link to learn more about the Momentum Grade.

As of February 04, 2026, Greenwich LifeSciences, Inc. has a weighted four-quarter relative price strength of 82.76%, which translates to a Momentum Score of 99 and is considered to be Very Strong.

Want to learn more about how Greenwich LifeSciences, Inc. is graded based on AAII’s composite scores for value, growth, quality and earnings estimate revisions? Subscribe to A+ Investor today.

Greenwich LifeSciences, Inc. Stock Price: Bottom Line

As of February 4, 2026, Greenwich LifeSciences, Inc.’s stock price is $27.010, which is down 3.62% from its previous closing price.

AAII advises against making stock decisions based solely on price or past returns. Instead, consider a variety of metrics, fundamentals, and analytics to evaluate a stock like Greenwich LifeSciences, Inc. stock prices are influenced by market supply and demand and offer just a snapshot of a company's overall health.

Subscribing to AAII's A+ Investor provides access to comprehensive analytics and insights for confident investing.